Date published: 2026-5-30

1-800-457-3801

SCBT Portrait Logo
Seach Input

Olr569 Inhibitors

Olr569 inhibitors are a specific class of chemical compounds that interact with the olfactory receptor 569 (Olr569). Olr569 is a part of the large family of G protein-coupled receptors (GPCRs), which play a crucial role in the detection of odor molecules. These inhibitors typically function by binding to the active site or allosteric sites on the Olr569 receptor, thereby modulating its activity. The structure of Olr569 inhibitors is often characterized by the presence of various functional groups that facilitate strong binding interactions with the receptor. These functional groups can include hydroxyl groups, aromatic rings, and other polar moieties that enhance the inhibitor's affinity and specificity for Olr569. The chemical diversity within this class allows for a wide range of binding affinities and selectivities, making them valuable for studying the specific mechanisms of olfactory signaling pathways.

The inhibition of Olr569 provides significant insights into the biochemical processes underlying olfaction. By studying these inhibitors, researchers can elucidate the structural and functional aspects of the Olr569 receptor, contributing to a broader understanding of GPCR-mediated signal transduction. This can involve the use of various biochemical and biophysical techniques, such as X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and computational modeling, to determine the precise binding interactions and conformational changes induced by the inhibitors. Additionally, Olr569 inhibitors can be used in experimental settings to investigate the receptor's role in olfactory sensory neurons, helping to map out the complex neural circuits involved in odor detection and perception. Through these studies, the molecular mechanisms by which Olr569 and its inhibitors influence olfactory responses are progressively uncovered, providing a foundation for further research into the intricate network of olfactory receptors and their ligands.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Dasatinib

302962-49-8sc-358114
sc-358114A
25 mg
1 g
$70.00
$145.00
51
(1)

Src family kinase inhibitor, may interfere with cell proliferation and survival signaling.

Lapatinib

231277-92-2sc-353658
100 mg
$420.00
32
(1)

Dual EGFR and HER2 inhibitor, potentially impacts cell signaling in HER2-positive cancers.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$57.00
$100.00
$250.00
129
(3)

RAF kinase and VEGFR inhibitor, potentially disrupts cell proliferation and angiogenesis.

Pazopanib

444731-52-6sc-396318
sc-396318A
25 mg
50 mg
$130.00
$182.00
2
(1)

Multi-targeted receptor tyrosine kinase inhibitor, may affect angiogenesis and tumor growth.

Vandetanib

443913-73-3sc-220364
sc-220364A
5 mg
50 mg
$167.00
$1353.00
(1)

Inhibits VEGFR, EGFR, and RET tyrosine kinases, potentially affecting cell growth and angiogenesis.

Afatinib-d4

850140-72-6 (unlabeled)sc-481821
10 mg
$4665.00
(0)

Irreversible inhibitor of EGFR, HER2, and HER4, potentially impacting cell proliferation pathways.

Lenvatinib

417716-92-8sc-488530
sc-488530A
sc-488530B
5 mg
25 mg
100 mg
$182.00
$661.00
$1690.00
3
(0)

Multi-targeted kinase inhibitor, could affect VEGFR, FGFR, PDGFR, RET, and KIT signaling pathways.

Tivozanib

475108-18-0sc-475339
5 mg
$320.00
(0)

VEGFR inhibitor, potentially disrupts angiogenesis and tumor growth.

Palbociclib

571190-30-2sc-507366
50 mg
$321.00
(0)

CDK4/6 inhibitor, potentially interrupts cell cycle progression in cancer cells.

Erlotinib Hydrochloride

183319-69-9sc-202154
sc-202154A
10 mg
25 mg
$75.00
$121.00
33
(1)

EGFR tyrosine kinase inhibitor, potentially alters cell signaling and proliferation in EGFR-mutated cancers.